EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Single-cell spatial landscape of immunotherapy response reveals mechanisms of CXCL13 enhanced antitumor immunity

Mark Sorin, Elham Karimi, Morteza Rezanejad, Miranda W Yu, Lysanne Desharnais, Sheri A C McDowell, Samuel Doré, Azadeh Arabzadeh, Valerie Breton, Benoit Fiset iD, Yuhong Wei, Roni Rayes und 8 weitere

Journal for ImmunoTherapy of Cancer · 2023-02 · 11 (2) · e005545

DOI: 10.1136/jitc-2022-005545 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 01.02.2023. Verfasst von Mark Sorin und 19 weiteren Autor:innen. Beteiligte Einrichtung: Rosalind and Morris Goodman Cancer Institute, McGill University, Montreal, Quebec, Canada. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 70-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: CIHR, Rosalind and Morris Goodman Chair in Lung Cancer Research, Fonds de Recherche du Québec - Santé.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Immunotherapy has revolutionized clinical outcomes for patients suffering from lung cancer, yet relatively few patients sustain long-term durable responses. Recent studies have demonstrated that the tumor immune microenvironment fosters tumorous heterogeneity and mediates both disease progression and response to immune checkpoint inhibitors (ICI). As such, there is an unmet need to elucidate the spatially defined single-cell landscape of the lung cancer microenvironment to understand the mechanisms of disease progression and identify biomarkers of response to ICI.

Methods

Here, in this study, we applied imaging mass cytometry to characterize the tumor and immunological landscape of immunotherapy response in non-small cell lung cancer by describing activated cell states, cellular interactions and neighborhoods associated with improved efficacy. We functionally validated our findings using preclinical mouse models of cancer treated with anti-programmed cell death protein-1 (PD-1) immune checkpoint blockade.

Results

We resolved 114,524 single cells in 27 patients treated with ICI, enabling spatial resolution of immune lineages and activation states with distinct clinical outcomes. We demonstrated that CXCL13 expression is associated with ICI efficacy in patients, and that recombinant CXCL13 potentiates anti-PD-1 response in vivo in association with increased antigen experienced T cell subsets and reduced CCR2+ monocytes.

Discussion

Our results provide a high-resolution molecular resource and illustrate the importance of major immune lineages as well as their functional substates in understanding the role of the tumor immune microenvironment in response to ICIs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsAnimalsMiceChemokine CXCL13Immune Checkpoint InhibitorsImmunotherapyTumor MicroenvironmentHumans

Stichwörter der Autor:innen

CytokinesImmunotherapyLung Neoplasms

Substanzen

Chemokine CXCL13Cxcl13 protein, mouseImmune Checkpoint InhibitorsCXCL13 protein, human

Autor:innen und Institutionen

  • Rosalind and Morris Goodman Cancer Institute, McGill University, Montreal, Quebec, Canada.
  • Department of Human Genetics, McGill University, Montreal, Quebec, Canada.
  • Department of Psychology and Computer Science, University of Toronto, Toronto, Ontario, Canada.
  • Department of Physiology, McGill University, Montreal, Quebec, Canada.
  • Institut Universitaire de Cardiologie et de Pneumologie de Québec, Université Laval, Québec City, Quebec, Canada.
  • Department of Medicine, Division of Experimental Medicine, McGill University, Montreal, Quebec, Canada.

ORCID-Profile: Benoit Fiset, Logan A Walsh

Förderung

  • CIHR
  • Rosalind and Morris Goodman Chair in Lung Cancer Research
  • Fonds de Recherche du Québec - Santé
  • Montreal General Hospital Foundation Dr. Ray Chiu Distinguished Scientist in Surgical Research Award.
  • Canadian Institutes of Health Research
  • Brain Tumor Funders' Collaborative
  • Fonds de recherche du Québec - Santé Doctoral award
  • Hilton J. McKeown Scholarship

Zitieren

APA

Sorin, M., Karimi, E., Rezanejad, M., Yu, M. W., Desharnais, L., McDowell, S. A. C., Doré, S., Arabzadeh, A., Breton, V., Fiset, B., Wei, Y., Rayes, R., Orain, M., Coulombe, F., Manem, V. S. K., Gagne, A., Quail, D. F., Joubert, P., Spicer, J. D., & Walsh, L. A. (2023). Single-cell spatial landscape of immunotherapy response reveals mechanisms of CXCL13 enhanced antitumor immunity. Journal for ImmunoTherapy of Cancer, 11(2), e005545. https://doi.org/10.1136/jitc-2022-005545

Vancouver

Sorin M, Karimi E, Rezanejad M, Yu MW, Desharnais L, McDowell SAC, et al. Single-cell spatial landscape of immunotherapy response reveals mechanisms of CXCL13 enhanced antitumor immunity. Journal for ImmunoTherapy of Cancer. 2023;11(2):e005545. doi:10.1136/jitc-2022-005545

BibTeX
@article{Sorin2023,
  author = {Sorin, Mark and Karimi, Elham and Rezanejad, Morteza and Yu, Miranda W and Desharnais, Lysanne and McDowell, Sheri A C and Doré, Samuel and Arabzadeh, Azadeh and Breton, Valerie and Fiset, Benoit and Wei, Yuhong and Rayes, Roni and Orain, Michele and Coulombe, Francois and Manem, Venkata S K and Gagne, Andreanne and Quail, Daniela F and Joubert, Philippe and Spicer, Jonathan D and Walsh, Logan A},
  title = {Single-cell spatial landscape of immunotherapy response reveals mechanisms of CXCL13 enhanced antitumor immunity},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2023},
  volume = {11},
  number = {2},
  pages = {e005545},
  doi = {10.1136/jitc-2022-005545}
}
Kostenlos starten →